Patients & Caregivers / Clinical Trials/Research Studies

text size: Default style Switch styles (larger text) Switch styles (largest text)
Clinical Trials/Research Studies - Recruiting


STARBEAM Study (Lundbeck)

Description: The primary objective of this study is to establish the efficacy of an investigational medication (Lu AE58054) as adjunctive therapy to Donepezil for symptomatic treatment of patients with mild-moderate Alzheimer's disease.

Study Length: 24 months

Study Requirements
  • Individuals age 50 or older with mild–moderate Alzheimer's disease
  • Not currently taking memantine
  • Stable treatment with donepezil
  • A study partner who will accompany the participant to all clinic visits
Contact:
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu



AMBAR Study

Description: The purpose of this study is to determine whether short-term followed by long-term, low-volume plasma exchange (a process of blood filtering) is able to modify Alzheimer Disease patient's cognitive, functional, and behavioral symptoms.

Study Length: 14 months (Six weekly plasmapheresis sessions followed by 12 monthly plasmapheresis sessions)

Study Requirements
  • 55-85 years of age
  • Individuals with a diagnosis of mild to moderate Alzheimer's disease
  • A study partner who will accompany the participant to all clinic visits
Contact:
Donna Simpson, 412-692-2717 or simpsondm@upmc.edu or
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu



Communication about Type 2 Diabetes Treatment in Older Adults with Memory Problems

Description: This study is investigating how diabetes treatment goals and medication decisions are made for older adults with both Type 2 Diabetes Mellitus (T2DM) and memory problems. We will be interviewing 12 informal (unpaid) caregivers of older adults with both T2DM and memory problems.

Study Length: Participation involves one telephone interview that takes 30-60 minutes. Participants will be compensated $40 for completing the interview.

Study Requirements
You may be eligible if you:
  • provide informal care to a spouse, relative, or friend who is 65 years of age or older and has both T2DM and memory problems
  • attend medical appointments with the person for whom you care
  • are age 18 or older
For more information, please contact: Loren Schleiden at 724-766-0361 or ljs24@pitt.edu



EXPEDITION 3 Clinical Trial

Description: This study will test the idea that the investigational medication solanezumab will slow the cognitive and functional decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.

Study Length: Approximately 18 months

Study Requirements
  • Individuals with a diagnosis of mild Alzheimer’s disease
  • Ages 55 – 90
  • A study partner who will accompany the participant to all clinic visits
Contact:
Carolyn Rickard at 412-692-2707 mishlercj@upmc.edu or
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu



Medication Study for the Treatment of Agitation in Moderate to Severe Alzheimer's Disease

Description: The purpose of this study is to determine whether an investigational medication (ELND005) is effective for reducing behaviors in people with moderate to severe Alzheimer's disease who have agitation/aggression.

Study Length: 12 Weeks

Study Requirements
  • Diagnosis of moderate to severe Alzheimer's disease with behavior problems/agitation.
  • A study partner who will accompany the participant to all clinic visits.
Contact: MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu